Replies to post #342599 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Anavex have competing drugs from “the other S2 receptor companies?” We certainly invite the posting of research or clinical data that might support such a contention. What are those other companies? What new drugs are they endorsing? Most importantly, what (if any) is the existing evidence of safety and efficacy? Lots for Anavex. For the other competing companies...?

One could start with the hint in the: post indirectly referred to. The company is Cognition Therapeutics and their lead drug is CT1812:

CT1812, is designed to restore damaged cellular processes such as autophagy, cholesterol synthesis and protein trafficking, which are dysregulated in neurodegenerative disorders. CT1812 binds to TMEM97, a protein component of the s-2 receptor, a key regulator of the cellular damage response. In Alzheimer’s disease, this results in the displacement of Aß oligomers, which are then cleared into the cerebrospinal fluid (CSF).

Our pipeline compounds uniquely target the sigma-2 (s-2) receptor, a key regulator of the cellular damage response.

Watch their HC Wainwright presentation here: L Ricciardi presentation at B Riley Neuroscience 2021

COGRX is funded by NIH, MJFF and their AD trials are run under the auspices of the Alzheimer's Clinical Trials Consortium (ACTC).

Then read the papers here: PUBLICATIONS

The company's drug, approach, funding, pipeline, aspirations, prospects, enthusiasm and uniqueness presented imo may sound just as 'we got this' to COGRX investors as Anavex does to some investors.

Note that COGRX is but one of several potential competitors to Anavex, which anyone can find and evaluate if so inclined.

In investing, not least in biotech, it is important to not fall in love with one stock and bias one's opinion against competitors even before having researched them properly and objectively.

PS! I am not currently invested in COGRX.